Galenica's Bichsel to Close Pharmaceutical Operations

Galenica AG's subsidiary, Bichsel, will halt its pharmaceutical manufacturing by the end of 2026. This decision follows a consultation process due to ongoing economic deficits and unsustainable facilities despite previous investments. The closure impacts 152 jobs, reduced from an anticipated 170, with a comprehensive social plan in place to support affected employees.

Bichsel aims to ensure the supply of vital products to customers until the closure. It will collaborate with customers during the transition to alternative suppliers. Meanwhile, Galenica's Laboratoire Golaz will take over the extemporaneous formulations business, crucial for healthcare providers and patients.